Abstract

Acute bacterial sinusitis is common, but currently recommended antibiotic treatment provides minimal benefit. To confirm the previous finding that high-dose amoxicillin plus clavulanate (with double the amount of amoxicillin) may be superior to standard-dose amoxicillin plus clavulanate in adults. This double-blind, comparative-effectiveness randomized clinical trial was conducted from February 26, 2018, through May 10, 2020, at the academic primary care internal medicine and pediatrics practice of Albany Medical Center, located in Cohoes, New York. Participants included adults aged 18 years or older who were prescribed amoxicillin plus clavulanate for acute bacterial sinusitis diagnosed in accordance with the Infectious Diseases Society of America guidelines. Amoxicillin 875 mg with clavulanate 125 mg plus either placebo (standard dose) or amoxicillin 875 mg (high dose) twice a day for 7 days. The primary efficacy outcome was a global rating of "a lot better" or "no symptoms" at the end of 3 days of treatment using a Global Rating of Improvement scale, with outcomes ranging from 1 (a lot worse) to 6 (no symptoms). The primary adverse effect outcome was severe diarrhea at 3 or 10 days after the start of treatment. At an unplanned interim analysis prompted by COVID-19 restrictions, 157 of a projected 240 participants had been enrolled (mean age, 48.5 [range, 18.7-84.0] years; 117 women [74.5%]), with 79 randomized to the standard dose and 78 to the high dose; 9 and 12, respectively, withdrew or were lost to follow-up before the assessment of the primary outcome. At day 3, 31 of 70 participants (44.3%) in the standard-dose group reported a global rating of "a lot better" or "no symptoms," as did 24 of 66 (36.4%) in the high-dose group, for a difference of -7.9% (95% CI, -24.4% to 8.5%; P = .35). The study was, therefore, stopped for futility. Diarrhea was common in both groups by day 3, with any diarrhea reported in 29 of 71 participants (40.8%) receiving the standard dose and 28 of 65 (43.1%) receiving the high dose and severe diarrhea reported in 5 of 71 (7.0%) and 5 of 65 (7.7%), respectively. The results of this randomized clinical trial suggest that adults treated for clinically diagnosed acute sinusitis did not appear to benefit from taking high-dose compared with standard-dose amoxicillin plus clavulanate. ClinicalTrials.gov Identifier: NCT03431337.

Highlights

  • Acute sinusitis is a common outpatient diagnosis and is typically treated with antibiotics even though the current recommended regimen (875 mg of amoxicillin with 125 mg of clavulanate by mouth twice a day)[1] has been shown in clinical trials to provide only minimal benefit beyond placebo.[2]

  • At an unplanned interim analysis prompted by COVID-19 restrictions, 157 of a projected 240 participants had been enrolled, with 79 randomized to the standard dose and 78 to the high dose; 9 and 12, respectively, withdrew or were lost to follow-up before the assessment of the primary outcome

  • The results of this randomized clinical trial suggest that adults treated for clinically diagnosed acute sinusitis did not appear to benefit from taking high-dose compared with standard-dose amoxicillin plus clavulanate

Read more

Summary

Introduction

Acute sinusitis is a common outpatient diagnosis and is typically treated with antibiotics even though the current recommended regimen (875 mg of amoxicillin with 125 mg of clavulanate by mouth twice a day)[1] has been shown in clinical trials to provide only minimal benefit beyond placebo.[2]. Few primary care clinicians will know this prevalence, and evidence from studies in children of the penetration of amoxicillin into middle ear fluid[3] and of the treatment of acute sinusitis with high-dose amoxicillin with clavulanate[4] suggests that higher-dose amoxicillin might provide more benefit to adults as well, even in areas with a low prevalence of penicillin-resistant pneumococci. The extendedrelease formulation provided no significant benefit, but the immediate-release formulation did; in the second, immediate-release part of the study, 52% of participants receiving the high dose rated symptoms as “a lot better” at the end of 3 days of treatment vs 34% receiving the standard dose (P = .04)

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call